200 related articles for article (PubMed ID: 35122491)
1. An assessment of liver lesions using a combination of CEUS LI-RADS and AFP.
Li CQ; Huang H; Ruan SM; Hu HT; Xian MF; Xie XY; Lu MD; Kuang M; Wang Y; Chen LD
Abdom Radiol (NY); 2022 Apr; 47(4):1311-1320. PubMed ID: 35122491
[TBL] [Abstract][Full Text] [Related]
2. Contrast-enhanced ultrasound Liver Imaging Reporting and Data System: Lights and shadows in hepatocellular carcinoma and cholangiocellular carcinoma diagnosis.
Vidili G; Arru M; Solinas G; Calvisi DF; Meloni P; Sauchella A; Turilli D; Fabio C; Cossu A; Madeddu G; Babudieri S; Zocco MA; Iannetti G; Di Lembo E; Delitala AP; Manetti R
World J Gastroenterol; 2022 Jul; 28(27):3488-3502. PubMed ID: 36158272
[TBL] [Abstract][Full Text] [Related]
3. Can contrast enhanced ultrasound differentiate intrahepatic cholangiocarcinoma from hepatocellular carcinoma?
Huang JY; Li JW; Ling WW; Li T; Luo Y; Liu JB; Lu Q
World J Gastroenterol; 2020 Jul; 26(27):3938-3951. PubMed ID: 32774068
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic Accuracy of CEUS LI-RADS for the Characterization of Liver Nodules 20 mm or Smaller in Patients at Risk for Hepatocellular Carcinoma.
Huang JY; Li JW; Lu Q; Luo Y; Lin L; Shi YJ; Li T; Liu JB; Lyshchik A
Radiology; 2020 Feb; 294(2):329-339. PubMed ID: 31793849
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic accuracy of contrast-enhanced ultrasound for the differential diagnosis of hepatocellular carcinoma: ESCULAP versus CEUS-LI-RADS.
Schellhaas B; Görtz RS; Pfeifer L; Kielisch C; Neurath MF; Strobel D
Eur J Gastroenterol Hepatol; 2017 Sep; 29(9):1036-1044. PubMed ID: 28562394
[TBL] [Abstract][Full Text] [Related]
6. Combining serum AFP and CEUS LI-RADS for better diagnostic performance in Chinese high-risk patients.
Gong W; Wu J; Wei H; Jiang Z; Wan M; Wu C; Xue W; Ma R; Zhou X; Zhou H
Radiol Med; 2023 Apr; 128(4):393-401. PubMed ID: 36943653
[TBL] [Abstract][Full Text] [Related]
7. LR-M Observations on Contrast-Enhanced Ultrasound: Detection of Hepatocellular Carcinoma Using Additional Features in Comparison With Current LI-RADS Criteria.
Xian MF; Huang Y; Xie WX; Pan KM; Zeng D; Huang H; Li MD; Xie XY; Kuang M; Lu MD; Chen LD; Wang W
AJR Am J Roentgenol; 2022 Jul; 219(1):76-85. PubMed ID: 34910538
[No Abstract] [Full Text] [Related]
8. Evaluation of LI-RADS 3 category by magnetic resonance in US-detected nodules ≤ 2 cm in cirrhotic patients.
Darnell A; Rimola J; Belmonte E; Ripoll E; Garcia-Criado Á; Caparroz C; Díaz-González Á; Vilana R; Reig M; Ayuso C; Bruix J; Forner A
Eur Radiol; 2021 Jul; 31(7):4794-4803. PubMed ID: 33409789
[TBL] [Abstract][Full Text] [Related]
9. Contrast-enhanced US diagnostic algorithm of hepatocellular carcinoma in patients with occult hepatitis B.
Huang Y; Li W; Hu HT; Ruan SM; Xian MF; Xie XY; Lu MD; Kuang M; Chen LD; Wang W
Abdom Radiol (NY); 2022 Feb; 47(2):608-617. PubMed ID: 34800160
[TBL] [Abstract][Full Text] [Related]
10. Contrast-enhanced ultrasound in association with serum biomarkers for differentiating combined hepatocellular-cholangiocarcinoma from hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
Yang J; Zhang YH; Li JW; Shi YY; Huang JY; Luo Y; Liu JB; Lu Q
World J Gastroenterol; 2020 Dec; 26(46):7325-7337. PubMed ID: 33362387
[TBL] [Abstract][Full Text] [Related]
11. Performance of current versus modified CEUS LI-RADS in the diagnosis of non-hepatocellular carcinoma malignancies.
Wen R; Huang F; Lin P; Gao R; Pang J; Wu Y; Yin H; Tang Z; Ma Z; He Y; Yang H
Abdom Radiol (NY); 2023 Dec; 48(12):3688-3695. PubMed ID: 37726380
[TBL] [Abstract][Full Text] [Related]
12. Differentiation between combined hepatocellular carcinoma and hepatocellular carcinoma: comparison of diagnostic performance between ultrasomics-based model and CEUS LI-RADS v2017.
Li CQ; Zheng X; Guo HL; Cheng MQ; Huang Y; Xie XY; Lu MD; Kuang M; Wang W; Chen LD
BMC Med Imaging; 2022 Mar; 22(1):36. PubMed ID: 35241004
[TBL] [Abstract][Full Text] [Related]
13. Combined hepatocellular-cholangiocarcinoma: can we use contrast-enhanced ultrasound Liver Imaging Reporting and Data System (LI-RADS) to predict the patient's survival?
Yang J; Huang JY; Chen X; Ling WW; Luo Y; Shi YJ; Liu JB; Lu Q; Lyshchik A
Eur Radiol; 2021 Aug; 31(8):6397-6405. PubMed ID: 33492470
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis of LI-RADS M lesions on gadoxetate-enhanced MRI: identifying cholangiocarcinoma-containing tumor with serum markers and imaging features.
Jiang H; Song B; Qin Y; Chen J; Xiao D; Ha HI; Liu X; Oloruntoba-Sanders O; Erkanli A; Muir AJ; Bashir MR
Eur Radiol; 2021 Jun; 31(6):3638-3648. PubMed ID: 33245494
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic value of CEUS LI-RADS and serum tumor markers for combined hepatocellular-cholangiocarcinoma.
Wen R; Lin P; Wu Y; Yin H; Huang W; Guo D; Peng Y; Liu D; He Y; Yang H
Eur J Radiol; 2022 Sep; 154():110415. PubMed ID: 35738166
[TBL] [Abstract][Full Text] [Related]
16. Differentiation of hepatocellular carcinoma from intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma in high-risk patients matched to MR field strength: diagnostic performance of LI-RADS version 2018.
Zou X; Luo Y; Morelli JN; Hu X; Shen Y; Hu D
Abdom Radiol (NY); 2021 Jul; 46(7):3168-3178. PubMed ID: 33660040
[TBL] [Abstract][Full Text] [Related]
17. LI-RADS-CEUS - Proposal for a Contrast-Enhanced Ultrasound Algorithm for the Diagnosis of Hepatocellular Carcinoma in High-Risk Populations.
Schellhaas B; Wildner D; Pfeifer L; Goertz RS; Hagel A; Neurath MF; Strobel D
Ultraschall Med; 2016 Dec; 37(6):627-634. PubMed ID: 27486793
[No Abstract] [Full Text] [Related]
18. Evaluation of contrast-enhanced ultrasound LI-RADS version 2017: application on 271 liver nodules in individuals with non-alcoholic steatohepatitis.
Huang Z; Zhou P; Li S; Li K
Eur Radiol; 2022 Oct; 32(10):7146-7154. PubMed ID: 35639147
[TBL] [Abstract][Full Text] [Related]
19. Contrast ultrasound LI-RADS LR-5 identifies hepatocellular carcinoma in cirrhosis in a multicenter restropective study of 1,006 nodules.
Terzi E; Iavarone M; Pompili M; Veronese L; Cabibbo G; Fraquelli M; Riccardi L; De Bonis L; Sangiovanni A; Leoni S; Zocco MA; Rossi S; Alessi N; Wilson SR; Piscaglia F;
J Hepatol; 2018 Mar; 68(3):485-492. PubMed ID: 29133247
[TBL] [Abstract][Full Text] [Related]
20. A modified LI-RADS: targetoid tumors with enhancing capsule can be diagnosed as HCC instead of LR-M lesions.
Min JH; Kim JM; Kim YK; Kim H; Choi GS; Kang TW; Cha D; Hwang JA; Ko SE; Ahn S
Eur Radiol; 2022 Feb; 32(2):912-922. PubMed ID: 34345947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]